Catálogo de publicaciones - libros
Risk-sharing in the Pharmaceutical Industry: The Case of Out-licensing
Gerrit Reepmeyer
Resumen/Descripción – provisto por la editorial
No disponible.
Palabras clave – provistas por la editorial
No disponibles.
Disponibilidad
| Institución detectada | Año de publicación | Navegá | Descargá | Solicitá |
|---|---|---|---|---|
| No detectada | 2006 | SpringerLink |
Información
Tipo de recurso:
libros
ISBN impreso
978-3-7908-1667-9
ISBN electrónico
978-3-7908-1668-6
Editor responsable
Springer Nature
País de edición
Reino Unido
Fecha de publicación
2006
Información sobre derechos de publicación
© Physica-Verlag Heidelberg 2006
Cobertura temática
Tabla de contenidos
Introduction
Palabras clave: Risk Management; Pharmaceutical Company; External Partner; Pharmaceutical Firm; Biotechnology Firm.
Pp. 1-27
Key Issues in Managing Pharmaceutical Innovation
Palabras clave: Pharmaceutical Industry; Pharmaceutical Company; Generic Drug; Patent Protection; Mass Customization.
Pp. 29-64
Risk-sharing as New Paradigm in Pharma R&D Collaborations
Palabras clave: Intellectual Property; Pharmaceutical Company; External Partner; Pharmaceutical Firm; Marketing Capability.
Pp. 65-88
Case Studies on Risk-sharing in Pharma R&D Collaborations
Palabras clave: Pulmonary Arterial Hypertension; Pharmaceutical Company; Venture Capital; License Agreement; External Partner.
Pp. 89-129
Characteristics of Risk-sharing in Pharma R&D Collaborations
Palabras clave: Pharmaceutical Company; Venture Capital; Venture Capital Investor; External Partner; Pharmaceutical Firm.
Pp. 131-181
Theoretical Basis for Risk-sharing in Pharma R&D Collaborations
Palabras clave: Pharmaceutical Company; Adverse Selection; Expected Profit; Indifference Curve; Potential Buyer.
Pp. 183-202
Managerial Recommendations for Risk-sharing in Pharma R&D Collaborations
Palabras clave: Pharmaceutical Company; Managerial Recommendation; Price Setting; Risk Transferability; Product Coverage.
Pp. 203-244
Conclusion
Palabras clave: Pharmaceutical Company; Adverse Selection; Price Setting; Case Study Analysis; Risk Transferability.
Pp. 245-262